Galanthamine containing transdermal applicator for the treatment

Details Galanthamine containing transdermal applicator for the treatment Galanthamine containing transdermal applicator for the treatment

1992-09-29

1999-08-03

Cintins, Marianne M.

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Web, sheet or filament bases; compositions of bandages; or...

424449, 514215, A61K 970, A61K 3155

Patent

active

059322381

ABSTRACT:
Galanthamine and the pharmaceutically suitable acid addition salts thereof can be used for the treatment of alcoholism; these compounds are released from adequate pharmaceutic formulations which are administered, e.g., orally, transdermally, or otherwise parenterally, in a continuous and controlled manner.

REFERENCES:
patent: 4663318 (1987-05-01), Davis
patent: 4761429 (1988-08-01), Blum et al.
patent: 4777173 (1988-10-01), Shrotryia et al.
patent: 5089267 (1992-02-01), Hille et al.
Haboubi, N.A. et al, Ann. Clin. Biochem. 23(4); 458-62 1986.
Hsu, L.L. et al., Alcohol Clin Exp Res 7(3); 249-55 1983.
Stojek, A et al., BR J Addict 82(8): 927-30; 1907.
Daunderer, M., Fortschr Med 101 (17); 778-80 1983.
Power, J.S. et al.; J.Clin. Pharmacol. 21(1); 57-60 1981.
Riley, E.P. et al., Alcohol Clin Exp Res 10(1); 50-53 1986.
Paskov, D.S.: "Galanthamine." in: New Neuromuscular Blocking Agents, 31:653-72 Springer-Verlag Berlin, Heidelberg, New York, Tokyo (Ed.) (1986).
Snorrason, E., Stefansson, J.G.: "Galanthamine hydrobromide in mania." Lancet, 337: 557 (1991).
Stojek, A., Napierala, K.: "Physostigmine in eyedrops decreases craving for alcohol in early withdrawal treated with carbamazepine." Materia Medica Polona, 4: 249-54 (1986).
Tanahashi, T., Poulev, a., Zenk, M.H.: "Radioimmunoassay for the quantitative determination of Galanthamine." Planta Medica, 56: 77-81 (1990).
Tencheva, J., Yamboliev, I., Zhivkova, Z.: "Reversed-phase liquid chromatography for the determination of galanthamine and its metabolites in human plasma and urine." Journal of Chromatography, 421: 396-400 (1987).
Thomsen, T., Bickel, U., Fischer, J.P., Kewitz, H.: "Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans." Eur. J. Clin. Pharmacol., 39: 603-5 (1990).
Thomsen, T., Zendeh, B., Fischer, J.P., Kewitz, H.: "In vitro effects of various cholinesterase inhibitors on acetyl- and butyrylcholinesterase of healthy volunteers." Biochemical Pharmacology, 41: 139-41 (1991).
Thomsen, T., Kaden, B., Fischer, J.P., Bickel, U., Barz, H., Gusztony, G., Cervos-Navarro, J., Kewitz, H.: "Inhibition of Acetylcholinesterase activity in human brain tissue and erythrocytes by Galanthamine, Physostigmine and Tacrine." Eur. J. Clin. Chem., Clin. Biochem. 29: 487-92 (1991).
Thomsen, T., Kewitz, H.: "Selective inhibition of human acetylcholinesterase by Galanthamine in vitro and in vivo." Life Sciences, 46: 1553-58 (1990).
Vlahov, R., Krikorian, D., Spassov, G., Chinova, M., Vlahov, I., Parushev, S., Snatzke, G., Ernst, L., Kieslich, K., Abraham, W.-R., Sheldrick, W.S.: "Synthesis of Galanthamine and related alkaloids--New approaches." Tetrahedron, 45: 3329-45 (1989).
J. Ruprecht et al: "The involvement of the central cholinergic and endorphinergic systems in the nitrous oxide withdrawl syndrome in mice." Anesthesiology, V. 58, No. 6, 1983, pp. 524-526.
Bickel, U., Thomsen, T., Weber, W., Fischer, J.P., Bachus, R., Nitz, M., Kewitz, H.: "Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition." Clin. Pharmacol. Ther., 50: 420-28 (1991).
Cozanitis, D.A., Toivakka, E.: "Treatment of respiratory depression with the anticholinesterase drug galanthamine hydrobromide." Aneasthesia, 29: 581-84 (1974).
Cozanitis, D.A.: "Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of Scopolamine (Hyoscine)." Anaesthesist, 26: 649-50 (1977).
Cozanitis, D.A., van de Pol, F., van Wezel, H., Crul, J.F.: "Antagonistic activity of galanthamine on constant infusion of pancuronium in rats." Experientia, 37: 1326-27 (1981).
Cozanitis, D.A., Friedmann, T., Furst, S.: "Study of the analgesic effects of Galanthamine, a Cholinesterase Inhibitor." Archives Inter. de Pharmacodynamie et de Teerapie, 266: 229-38 (1983).
Foitzik, H., Lawin, P.: "Klinische Erfahrungen mit Galanthamin (Nivalin) als Antidot von Pancuronium." Z. prakt. Anasth., 7:203-7 (1972).
Gopel, W., Bertram, W.: "Erfahrung mit Nivalin in der neurologischen Therapie." Psychiat. Neurol. med. Psychol., 23: 712-18 (1971).
Mayrhofer, O.: "Erfahrungen mit Galanthamin (Nivalin) als Antagonist der Relaxantien vom Curaretyp." Bull. schweiz. Akad. med. Wiss., 23: 48-52 (1967).
Mihailova, D., Yamboliev, I., Zhivkova, Z., Tencheva, J., Jovovich, V.: "Pharmacokinetics of Galanthamine Hydrobromide after single subcutaneous and oral dosage in humans." Pharmacology, 39: 50-58 (1989).
Naranjo, C.A., Sellers, E.M. (Ed.): "Drug treatments for alcoholism: The need for innovation." "Drug treatments for alcoholsm: The need for innovation." in: Research Advances in New Psychopharm. Treatments for Alcoholism, 1-9 Elsevier Science Publishers B.V. (1985).
Baraka, A., Harik, S.: "Reversal of central anticholinergic syndrome by Galanthamine." JAMA, 238: 2293-94 (1977).
Bastida, J., Viladomat, F., Llabres, J.M., Quiroga, S., Codina, C., Rubiralta, M.: "Narcissus nivalis: A new source of Galanthamine." Planta Medica, 56: 123-24 (1990).

Affiliated with

Also associated with

Rating

Galanthamine containing transdermal applicator for the treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Galanthamine containing transdermal applicator for the treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Galanthamine containing transdermal applicator for the treatment will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-847547